[go: up one dir, main page]

AR122507A1 - Inhibidores de tmprss2 y métodos de uso - Google Patents

Inhibidores de tmprss2 y métodos de uso

Info

Publication number
AR122507A1
AR122507A1 ARP210101502A ARP210101502A AR122507A1 AR 122507 A1 AR122507 A1 AR 122507A1 AR P210101502 A ARP210101502 A AR P210101502A AR P210101502 A ARP210101502 A AR P210101502A AR 122507 A1 AR122507 A1 AR 122507A1
Authority
AR
Argentina
Prior art keywords
heteroaryl
group
optionally substituted
phenyl
membered
Prior art date
Application number
ARP210101502A
Other languages
English (en)
Inventor
Stephen J Shuttleworth
Original Assignee
Topspin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topspin Therapeutics Inc filed Critical Topspin Therapeutics Inc
Publication of AR122507A1 publication Critical patent/AR122507A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La divulgación provee compuestos y su uso en el tratamiento de enfermedades o trastornos médicos, tales como una infección por coronavirus. Se proveen composiciones farmacéuticas y métodos para hacer varios compuestos. Se contempla que los compuestos inhiban proteasas, tales como la proteasa de serina transmembrana 2. Un compuesto representado por: fórmula (1), en donde: A se selecciona del grupo que consiste en fenilo, naftilo, heteroarilo de 5 - 6 miembros, alquilo C₁₋₆ y cicloalquilo C₁₋₆, en donde A está opcionalmente sustituido con uno, dos o tres sustituyentes cada uno seleccionado, de modo independiente, del grupo que consiste en RA; B se selecciona del grupo que consiste en heteroarilo monocíclico de 5 - 6 miembros, heteroarilo bicíclico de 8 - 10 miembros y heterociclilo bicíclico de 8 - 10 miembros, en donde B contiene al menos un nitrógeno y B está opcionalmente sustituido en uno, dos o tres carbonos con un sustituyente cada uno seleccionado, de modo independiente, de RB; en donde, cuando dicho heterociclilo contiene un resto -NH, el nitrógeno de -NH puede estar opcionalmente sustituido con uno o más sustituyentes seleccionados cada uno de Rʰ; W se selecciona de fenilo y heteroarilo, en donde W está sustituido en un carbono con un resto de ojiva Rʷ, en donde Rʷ se selecciona del grupo que consiste en amidina, amidoxima, guanidina y N-hidroxiguanidina; un compuesto representado por: fórmula (2), en donde: C y D se seleccionan de modo independiente, para cada aparición, del grupo que consiste en fenilo y heteroarilo monocíclico de 5 - 6 miembros, en donde el fenilo o heteroarilo monocíclico de 5 - 6 miembros puede estar opcionalmente sustituido con uno o más sustituyentes seleccionados cada uno de Rᵍ; B se selecciona del grupo que consiste en heteroarilo monocíclico de 5 - 6 miembros, heteroarilo bicíclico de 8 - 10 miembros y heterociclilo bicíclico de 8 - 10 miembros, en donde B contiene al menos un nitrógeno y B está opcionalmente sustituido en uno, dos o tres carbonos con un sustituyente cada uno seleccionado, de modo independiente, de RB; en donde, cuando dicho heterociclilo contiene un resto -NH, el nitrógeno de -NH puede estar opcionalmente sustituido con uno o más sustituyentes seleccionados cada uno de Rʰ; W se selecciona de fenilo y heteroarilo, en donde W está sustituido en un carbono con un resto de ojiva Rʷ, en donde Rʷ se selecciona del grupo que consiste en amidina, amidoxima, guanidina y N-hidroxiguanidina; un compuesto representado por: fórmula (3), en donde: A se selecciona del grupo que consiste en fenilo, naftilo y heteroarilo de 5 - 6 miembros, en donde A está opcionalmente sustituido con uno, dos o tres sustituyentes cada uno seleccionado, de modo independiente, del grupo que consiste en RA.
ARP210101502A 2020-06-02 2021-06-02 Inhibidores de tmprss2 y métodos de uso AR122507A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063033709P 2020-06-02 2020-06-02

Publications (1)

Publication Number Publication Date
AR122507A1 true AR122507A1 (es) 2022-09-14

Family

ID=76641841

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101502A AR122507A1 (es) 2020-06-02 2021-06-02 Inhibidores de tmprss2 y métodos de uso

Country Status (7)

Country Link
US (1) US20240132457A1 (es)
EP (1) EP4157825A1 (es)
JP (1) JP2023529167A (es)
CN (1) CN116323572A (es)
AR (1) AR122507A1 (es)
TW (1) TW202210463A (es)
WO (1) WO2021247732A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
US7141596B2 (en) * 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
DE102011108346A1 (de) * 2011-07-25 2013-01-31 Philipps-Universität Marburg Verwendung von Hemmstoffen der TMPRSS2 als Arzneimittel

Also Published As

Publication number Publication date
US20240132457A1 (en) 2024-04-25
TW202210463A (zh) 2022-03-16
JP2023529167A (ja) 2023-07-07
EP4157825A1 (en) 2023-04-05
CN116323572A (zh) 2023-06-23
WO2021247732A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
PE20221339A1 (es) Inhibidores de parp1
ECSP22071009A (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
AR126914A1 (es) Inhibidores de ras novedosos
AR066972A1 (es) Derivados azapeptidicos
MX2019004578A (es) Oxisteroles y metodos de uso de los mismos.
AR087046A2 (es) Compuestos derivados de 4-oxoquinolina
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
DOP2013000062A (es) Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas
NZ725860A (en) Indole derivatives for use in medicine
EA200970805A1 (ru) Ингибиторы серинпротеаз для лечения hcv инфекций
AR126912A1 (es) Compuestos de 6-aminopirazolopirimidina y su uso médico
CU20150084A7 (es) Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral)
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
CU20230009A7 (es) Composiciones farmacéuticas que comprenden compuestos derivados de (r)-n-(5-(3-hidroxipirrolidin-1-il)-2-morfolinooxazolo[4,5-b]piridin-6- il)-2-(2-metilpiridin-4-il) oxazol-4 -carboxamida, útiles como inhibidores de irak
CO2022006965A2 (es) Inhibidores de egfr
AR128066A1 (es) Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos
CO2024011857A2 (es) Compuestos de uracilo n3-sustituidos como inhibidores de trpa1
AR071049A1 (es) Uso de n- fenilamidas de acido 2- sulfonilaminobenzoidco sustituidas con sulfonilo en el tratamiento del dolor
AR043563A1 (es) Inhibidores de catepsina s
AR122507A1 (es) Inhibidores de tmprss2 y métodos de uso
CL2022002490A1 (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
UY38006A (es) Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones
PE20201148A1 (es) Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
PH12019500742A1 (en) Urea derivative
EA200600760A1 (ru) Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их

Legal Events

Date Code Title Description
FA Abandonment or withdrawal